Equities research analysts predict that Mesoblast limited (NASDAQ:MESO) will report earnings of ($0.24) per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for Mesoblast’s earnings, with estimates ranging from ($0.25) to ($0.22). Mesoblast reported earnings of ($0.08) per share during the same quarter last year, which would indicate a negative year over year growth rate of 200%. The firm is scheduled to issue its next quarterly earnings results on Tuesday, November 13th.
According to Zacks, analysts expect that Mesoblast will report full year earnings of ($1.01) per share for the current fiscal year, with EPS estimates ranging from ($1.12) to ($0.95). For the next financial year, analysts forecast that the company will report earnings of ($0.81) per share, with EPS estimates ranging from ($1.09) to ($0.53). Zacks’ earnings per share calculations are an average based on a survey of research analysts that cover Mesoblast.
Mesoblast (NASDAQ:MESO) last released its quarterly earnings results on Wednesday, August 29th. The company reported ($0.22) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.01. Mesoblast had a negative return on equity of 10.48% and a negative net margin of 203.51%. The company had revenue of $1.70 million for the quarter, compared to analysts’ expectations of $2.51 million.
A number of research analysts have commented on MESO shares. Cantor Fitzgerald set a $23.00 price target on Mesoblast and gave the stock a “buy” rating in a research note on Monday, October 1st. ValuEngine upgraded Mesoblast from a “hold” rating to a “buy” rating in a research note on Wednesday, September 26th. Zacks Investment Research upgraded Mesoblast from a “hold” rating to a “buy” rating and set a $6.75 price target on the stock in a research note on Wednesday, September 19th. HC Wainwright set a $17.00 price objective on Mesoblast and gave the company a “buy” rating in a research note on Tuesday, September 18th. Finally, Maxim Group increased their price objective on Mesoblast from $14.00 to $16.00 and gave the company a “buy” rating in a research note on Wednesday, July 18th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. Mesoblast has an average rating of “Buy” and an average target price of $14.13.
NASDAQ:MESO traded up $0.19 during trading hours on Friday, reaching $7.58. 121,888 shares of the stock were exchanged, compared to its average volume of 49,690. The company has a quick ratio of 4.21, a current ratio of 4.21 and a debt-to-equity ratio of 0.11. Mesoblast has a twelve month low of $4.74 and a twelve month high of $8.78. The stock has a market capitalization of $762.78 million, a price-to-earnings ratio of -12.03 and a beta of 1.96.
A hedge fund recently bought a new stake in Mesoblast stock. Jane Street Group LLC acquired a new stake in Mesoblast limited (NASDAQ:MESO) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 17,731 shares of the company’s stock, valued at approximately $102,000. Institutional investors and hedge funds own 2.74% of the company’s stock.
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.
Further Reading: Compound Interest and Why It Matters When Investing
Get a free copy of the Zacks research report on Mesoblast (MESO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.